Received prior radiotherapy to any portion of the abdominal cavity or pelvis
Patients with extra-abdominal metastatic disease
Radiation to the abdominal area within 28 days of first dose of therapy
Patients who have had prior abdominal radiotherapy
Subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
Prior radiation to the liver or other upper abdominal regions
Known or suspected extensive abdominal adhesions
Prior radiotherapy to any portion of the abdominal cavity or pelvis
Patients must be reasonable candidates for laparoscopy and IP platinum regimen with no prior evidence of clinically significant intra-abdominal adhesions, persistent abdominal wall infections, renal toxicity, or bowel obstruction
Prior abdominal radiotherapy
Prior history of abdominal radiation therapy
Patients with prior radiation to the abdominal cavity or pelvis are excluded
Subjects received previous abdominal radiation
Intra-abdominal disease > 8 cm in diameter at the time of registration, intrahepatic disease, or disease beyond the abdominal cavity; patients with intra-abdominal lymph node involvement are eligible based on biodistribution data indicating viral dissemination to lymph nodes following intraperitoneal administration
Prior history of abdominal radiation therapy
No prior abdominal radiation
Radiologic workup must demonstrate that the disease is confined to the abdominal cavity and/or is not metabolically active on PET (positron emission tomography scan), outside of the abdominal cavity
Patients will be ineligible if they have disease outside of the abdominal cavity which is uncontrolled or PET avid
Received prior radiotherapy to any portion of the abdominal cavity or pelvis.
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
Patient must be eligible for abdominal surgery
Subjects who have received prior radiation therapy to any portion of the abdominal cavity or pelvis are excluded; prior intravaginal brachytherapy is permitted; prior radiation therapy for breast cancer is permitted
Radiologic workup must demonstrate that the disease is confined to the abdominal cavity and/or is controlled outside of the abdominal cavity
Patients will be ineligible if they have disease outside of the abdominal cavity which is uncontrolled
Patients who have had prior abdominal radiotherapy
Patients with liver metastases cannot have received prior upper abdominal radiation
Patients who have received previous abdominal radiation
Patients who have had prior abdominal radiotherapy
Prior abdominal radiotherapy
Patients with evidence of abdominal free air not explained by paracentesis
Pfannenstiel or transverse abdominal incision
Prior radiotherapy to the abdomen or pelvis
INELIGIBLE SITES: Head and neck, visceral organs (with the exception of embryonal sarcoma of the liver), retroperitoneum, peritoneum, pelvis within the confines of the bony pelvis
MRI of pelvis within 90 days prior to registration
Have a history of prior radiotherapy to the whole pelvis.
History of radiation to the pelvis
Have received prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.
Prior radiation to the pelvis.
No prior radiotherapy to the prostate or lower pelvis
Prior radiation therapy to the pelvis
Patients with metastatic disease outside of the pelvis
Prior radiation therapy to the pelvis
Prior radiotherapy to the pelvis (or abdomen if para-aortic nodes are involved)
No prior radiotherapy to the prostate or lower pelvis
Prior radiation treatment to the pelvis
Patients with localized sarcomas that are not of the extremity or trunk wall (including head/neck, retroperitoneum, visceral organs, peritoneum, pelvis within the confines of the bony pelvis, and tumors arising in bone)
Prior radiation therapy to the pelvis
8 weeks if prior craniospinal chemoradiation therapy (CRT) or if ? 50% radiation of pelvis.
Prior history of radiation to the pelvis
Previous radiation therapy to the pelvis.
Any prior radiotherapy to the pelvis or abdomen
Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation.
Prior radiation treatment of > 45 gray (Gy) to the pelvis
Prior radiation therapy to the abdomen or pelvis
Women with prior radiotherapy to the pelvis or retroperitoneal surgery
Women with metastatic disease outside of pelvis
Concurrent use of other anti-cancer agents or treatment or concurrent radiation to the pelvis; palliative radiation to areas outside the pelvis is allowed
Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
Prior radiotherapy to the pelvis
Prior radiation to the pelvis or abdomen in the metastatic or locally advanced setting.
Previous radiotherapy to the pelvis
Have had prior dissection and/or radiation in pelvis.
Metastatic disease outside the confines of the abdomen and pelvis (such as lung, bone, brain)
Prior radiotherapy to the pelvis or abdomen
Received or will receive radiation therapy to the abdomen or pelvis in the week prior to study drug administration and/or during the course of the study
Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration)
Any history of metastatic TCC; subjects with suspected malignant lymphadenopathy in the abdomen or pelvis are not allowed
Radiation treatment to pelvis
Prior radiotherapy to the pelvis or prostate
Patients who have previously undergone radiation treatment to the pelvis
Ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study
Patients who have had prior radiation to the pelvis
Has received or will receive total body irradiation of radiation therapy to the abdomen or pelvis in the week prior to Treatment Day 1 and/or during the diary reporting period (120 hours following initiation of chemotherapy)
Patients with no prior radiation therapy to the pelvis
CT or magnetic resonance (MR) scan of abdomen and pelvis which does not suggest presence of metastatic disease outside of the pelvis
Metastatic disease outside of pelvis on any imaging or biopsy
Patient must not have undergone major surgery or radiotherapy to the pelvis or abdomen within previous 4 weeks
Previous radiation treatment of the pelvis
Radiotherapy to the abdomen or pelvis within 6 months of the screening visit
Any and all primary disease sites in the abdomen and pelvis will be allowed
A working diagnosis of malignancy in the liver, brain, H&N, or pelvis
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis within the last three years are excluded; prior vaginal brachytherapy is allowed; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than two years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer, provided that it was completed more than 2 years prior to registration, and the patient remains free of recurrent or metastatic disease and hormonal therapy has been discontinued; patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded; prior radiation for localized cancer of the head and neck or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of ovarian, fallopian tube, or primary peritoneal cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation therapy for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of cervical cancer within the last three years are excluded            \r\n* Prior radiation for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
Radiation therapy: patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
